NEXT Financial Group Inc Buys 625 Shares of Novo Nordisk A/S (NVO)

NEXT Financial Group Inc raised its stake in Novo Nordisk A/S (NYSE:NVO) by 15.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,790 shares of the company’s stock after buying an additional 625 shares during the period. NEXT Financial Group Inc’s holdings in Novo Nordisk A/S were worth $185,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fiera Capital Corp boosted its position in shares of Novo Nordisk A/S by 6.5% in the fourth quarter. Fiera Capital Corp now owns 148,921 shares of the company’s stock valued at $5,340,000 after buying an additional 9,074 shares during the last quarter. Banco Santander S.A. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $1,816,000. Menora Mivtachim Holdings LTD. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $137,000. Round Hill Asset Management purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $1,863,000. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Novo Nordisk A/S by 4.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 29,214 shares of the company’s stock valued at $1,050,000 after buying an additional 1,232 shares during the last quarter. Hedge funds and other institutional investors own 6.38% of the company’s stock.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE NVO) opened at 43.20 on Friday. The stock has a market capitalization of $107.82 billion, a PE ratio of 18.86 and a beta of 0.67. The company’s 50-day moving average price is $41.60 and its 200 day moving average price is $36.77. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $57.41.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/06/17/next-financial-group-inc-increases-position-in-novo-nordisk-as-nvo-updated-updated-updated.html.

Several research analysts have recently issued reports on NVO shares. HSBC Holdings plc cut Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Monday, March 20th. Barclays PLC started coverage on Novo Nordisk A/S in a research note on Tuesday, March 7th. They issued an “underweight” rating for the company. BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $57.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply